Open Access

New frontiers in ASCVD risk reduction: integrating icosapent ethyl in clinical practice

Event: ESC Congress 2022
Topic: Lipid-Lowering Agents
Session type: Satellite Symposium
Organised by PACE-CME - Supported by an unrestricted educational grant from Amarin Pharma
Date: 26 August 2022
Time: 15:30 - 16:15

Congress Session

This content is currently on OPEN ACCESS

Sign in to view the resources

5 presentations in this session

Introduction.

Speaker: Professor L. Badimon (Barcelona, ES)
Thumbnail

ASCVD & residual risk: recent clinical insights with icosapent ethyl.

Speaker: Professor D. Bhatt (Boston, US)
Thumbnail

A continuum of multifactorial benefits of icosapent ethyl.

Speaker: Professor M. Back (Stockholm, SE)
Thumbnail

Integrating icosapent ethyl in clinical practice: which patients will benefit?

Speaker: Professor S. Verma (Toronto, CA)
Thumbnail

Discussion.

Speaker: Professor L. Badimon (Barcelona, ES)
Thumbnail

5 speakers from this session

Professor Lina Badimon

Cardiovascular Program-ICCC, IR-Hospital de la Santa Creu i Sant Pau, UAB, CIBERCV, Barcelona (Spain)
16 presentations
1 follower

Professor Deepak Bhatt

Harvard Medical School, Boston (United States of America)
36 presentations
2 followers

Professor Magnus Back

Karolinska University Hospital, Stockholm (Sweden)
7 presentations
0 follower

Professor Subodh Verma

St. Michael's Hospital, Toronto (Canada)
20 presentations
0 follower

Professor Lina Badimon

Cardiovascular Program-ICCC, IR-Hospital de la Santa Creu i Sant Pau, UAB, CIBERCV, Barcelona (Spain)
16 presentations
1 follower

This platform is supported by

logo Novo Nordisk